Why the study?
Does a newer antihypertensive regimen (amlodipine +/- perindopril) and/or atorvastatin reduce non-fatal MI and fatal CHD compared to an older regimen (atenolol +/- bendroflumethiazide) and/or placebo in hypertensive patients with multiple risk factors?
RCT (n=19,342)
Open, blinded endpoint; double-blind for factorial component
2 x 2 factorial
Yes
Does a newer antihypertensive regimen (amlodipine +/- perindopril) and/or atorvastatin reduce non-fatal MI and fatal CHD compared to an older regimen (atenolol +/- bendroflumethiazide) and/or placebo in hypertensive patients with multiple risk factors?
Answers are grounded in this paper and cite their sources.
The ASCOT trial was designed to evaluate whether a newer antihypertensive regimen (amlodipine-based) and atorvastatin are superior to an older regimen (atenolol-based) and placebo in preventing CHD in hypertensive patients with multiple risk factors.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sever et al. (2001) conducted an RCT in Hypertension (n=19,342). Amlodipine +/- perindopril (with atorvastatin factorial) vs. Atenolol 50/100 mg +/- bendroflumethiazide 1.25/2.5 mg (with placebo factorial) was evaluated on Non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: